Arndt Vogel· @ArndtVogel · X·· 2 天前评分90
正文 · 原文
G-HOPE-001 phs-3: Arcotatug tavatecan vs TPC in previously treated G/GEJA: First interim analysis
#ESMO26 #ESMOAmbassadors
🇨🇳🇯🇵, 2600 prescreened, 430 included
👉ORR: 37 vs 7.7%
👉 mPFS: 7.1 vs 3.1 mo
👉 mOS: 10.2 vs 6.9 mo
🧐CLDN-2 ADC, strong signal of efficacy, acceptable safety
@myESMO @ASCO
1800 浏览 · 28 赞 · 17 转发 · 0 回复
会议摘要
LBA77按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G
https://esmocongress.esmo.org来源：Arndt Vogel · x.com